Bacillus polyfermenticus SCD, commonly referred to as Bispan strain, is used as a host in bioindustry and has been shown to have several human health benefits. In a recent in vitro study, we discovered that B. polyfermenticus SCD exerts cholesterol-lowering and antioxidant effects. Here, we evaluate the effects of B. polyfermenticus SCD on the lipid and antioxidant metabolisms of hypercholesterolemic rats. Twenty male Sprague-Dawley rats were divided into two groups after a 1-week adaptation period and were fed for 6 weeks on either a high fat-high cholesterol diet, or a high fat-high cholesterol diet supplemented with B. polyfermenticus SCD (3.1؋10 6 cfu/d). B. polyfermenticus SCD significantly reduced plasma low-density-lipoprotein cholesterol, hepatic total cholesterol, and triglycerides, while increasing the fecal excretion rates of total cholesterol and triglycerides. In addition, B. polyfermenticus SCD might reduce the risk of atherosclerosis, as the ratio of high-density-lipoprotein cholesterol to total cholesterol was significantly higher than in the control group. B. polyfermenticus SCD led to an increase in total radical trapping antioxidant potential (TRAP) and a decrease in conjugated dienes in plasma. The erythrocytic glutathione peroxidase (GSH-Px) activity in the B. polyfermenticus group was significantly lower than that in the control group. Plasma TRAP levels exhibited a highly significant negative correlation with hepatic total cholesterol and a marginally significant negative correlation with total plasma cholesterol, while a significant positive correlation was detected between fecal total cholesterol and plasma TRAP. These results suggest that B. polyfermenticus SCD exerts significant health benefits through the modulation of physiologic functions including a variety of atherogenic lipid profiles and antioxidants in hypercholesterolemia.
1)
Recently, hypercholesterolemia has been associated with enhanced oxidative stress related to increased lipid peroxidation.
2) Increased generation of oxidized low-density-lipoprotein (LDL) is a major factor in the vascular damage associated with high cholesterol levels.
3) Therefore the inhibition of oxidative stress under hypercholesterolemic conditions is considered to be an important therapeutic approach, and many efforts have been made to identify the antioxidative functions of various materials, including medicinal plants as dietary additives.
Numerous drugs that lower cholesterol, including 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA) inhibitors like lovastatin and simvastatin, which inhibit cholesterol biosynthesis, have been used to treat hypercholesterolemia. 4) However, the undesirable side effects of these compounds have raised concerns regarding their therapeutic use. 5) Probiotics, defined as the use of viable microbial dietary supplements that beneficially affect the host through their effects on the intestinal tract, are quickly gaining attention. In this era of self-care and complementary medicine, probiotic techniques are being increasingly utilized in the search for functional foods. 6) Since Shaper et al. 7) and Mann 8) observed that the consumption of large quantities of fermented milk containing a wild Lactobacillus by the Samburu and Masai tribes of Africa resulted in reductions in serum cholesterol levels, the ingestion of probiotic lactic acid bacteria has been pursued as a more natural way to decrease human cholesterol levels. It has been also reported that probiotic bacteria or their extracts exert antioxidative effects in vitro, [9] [10] [11] and exhibit a protective effect against hemolysis in vitamin E-deficient rats.
12)
Strains of Bacillus polyfermenticus SCD, commonly known as Bispan strains commercially, have been used in the treatment of long-term intestinal disorders, as the live strains are able to access the intestines in the form of active endospores. 13 ) B. polyfermenticus strain was first isolated from an air sample by Dr. Terakado in 1933. It produces a variety of enzymes, most of which can lyse pathogenic strains such as typhoid bacillus, paratyphoid bacillus, shigella, and cholera. Moreover, the uptake of B. polyfermenticus strains promotes human digestion, serving as a source of vitamins B 1 and B 2 and bolstering protection against nonoral infections and oral immunization. 14) B. polyfermenticus strains are described in the Japanese Pharmacopoeia as amylolytic bacilli, together with Bacillus subtilis and Bacillus mesentericus. However, the term Bispan does not appear in international nomenclature such as Bergey's Manual of Systematic Bacteriology. 15) Several studies have suggested that B. polyfermenticus SCD is significantly similar to B. subtilis strains in terms of their morphologic and biochemical properties. 13) However, B. polyfermenticus SCD is distinct from B. subtilis strains, as the former are capable of metabolizing lactose and produce a larger amount of acetic and lactic acid from glucose and lactose, respectively, than the latter.
In a recent in vitro experiment, we have determined that B. polyfermenticus has cholesterol-reducing activity, and exerted antioxidative effects.
16) The objective of this study was therefore to evaluate B. polyfermenticus SCD with regard to its use as an agent for improving plasma, hepatic, and fecal lipid profiles. Thus we attempted to characterize its cholesterol-lowering and antioxidant effects on rats who were fed a high-fat and high-cholesterol diet.
MATERIALS AND METHODS

Bacterial Strains and Media
The producer strain of B. polyfermenticus SCD was maintained at Ϫ70°C in a tryptic soy broth (TSB, Difco) to which 20% (v/v) glycerol was added. Working cultures were propagated in TSB, with shaking, at 37°C.
Production of B. polyfermenticus SCD B. polyfermenticus SCD production was performed as previously described. 14) In brief, B. polyfermenticus SCD was inoculated into 60 ml of sterile TSB (Difco), and the seed culture (2%, v/v) was then transferred to a jar fermenter (3-l working volume; Korea Fermenter Co., Korea). Temperature was maintained at 37°C, and pH was maintained at 7.0Ϯ0.1. B. polyfermenticus SCD was obtained by centrifugation (10000 rpm, 30 min) of the resulting stationary-phase cells after 72 h of incubation. The pellets were then freeze-dried and stored at 4°C.
Animals and Diets Eight-week-old male Sprague Dawley rats (nϭ20) were purchased from Samtako Inc. (Osan, Korea) and housed and cared for in accordance with the Guide for Care and Use of Laboratory Animals (Department of Health, Education, and Welfare, 1985) . The rats were allowed free access to water and fed for the first week with a commercially prepared pelleted diet for adjustment. The rats were then randomly divided into three groups of 10 animals each, and fed on either a high-fat and high-cholesterol diet (control group), or a high-fat and high-cholesterol diet supplemented with B. polyfermenticus SCD (3.1ϫ10 6 cfu/d) (B. polyfermenticus group) for 6 weeks. The composition of the fat and cholesterol-enriched diet was (g/100 g): casein, 20; corn starch, 42.949; sucrose, 10; corn oil, 5; lard, 12; cholesterol, 1; cellulose, 4; vitamin mixture (AIN-93; American Institute of Nutrition, 1993), 1; mineral mixture (AIN-93; American Institute of Nutrition, 1993), 3.5; choline bitartrate, 0.25; DL-methionine, 0.3; and butylated hydroxy toluene, 0.001. Animals were monitored daily for general health, and body weights were recorded every week for the duration of the study. Feces were collected during the final 3 d and were used to determine fecal lipid profiles. At the end of the experimental period, the rats were anesthetized with ethyl ether, and blood was collected from the abdominal artery in a heparinated sterile tube. Plasma was obtained from the blood samples by centrifugation (1500 rpm for 30 min) and stored at Ϫ80°C until required for further analysis. Erythrocytes were washed three times with isoosmotic phosphate-buffered saline (PBS), at a pH of 7.4, and resuspended to the original volume. The erythrocyte suspensions were frozen at Ϫ80°C until required for final analysis. Livers were removed from the rats and washed with ice-cold saline, at which time they were stored at Ϫ80°C before analysis.
Plasma Aspartate Transaminase and Alanine Transaminase Activities, and Protein and Lipid Profiles Plasma aspartate transaminase (AST), alanine transaminase (ALT), glucose, total protein, albumin, uric acid, and lipid profiles [total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides] were measured using enzymatic colorimetry methods with a commercial kit (Sigma Chemical Co.) and a photometric autoanalyzer (SEAC, CH-100 plus, Italy). Plasma LDL cholesterol levels were calculated using the formula developed by Friedewald et al. 17) Liver and Fecal Lipid Profiles Hepatic and fecal lipids were extracted according to the procedure developed by Folch et al. 18) Hepatic cholesterol and triglycerides were analyzed with the same enzymatic kit as used in the plasma analysis.
Erythrocytic Antioxidant Enzyme Activities Erythrocytic hemolysates were prepared by the dilution of erythrocytes to 1 : 20 (GSH-Px) and 1 : 500 (catalase) with distilled H 2 O. The protein contents of the erythrocytic hemolysates were determined using the Bio-Rad DC protein assay (Biorad, Hercules, CA, U.S.A.) with bovine serum albumin used as a reference protein. GSH-Px was determined according to the method described by Beutler. 19) Erythrocytic hemolysate 10 ml or liver tissue preparation was added to 100 ml of 1 M Tris-HCl 5 mM EDTA buffer (pH 8.0), 20 ml of glutathione 0.1 M, 100 ml of glutathione reductase 10 U/ml, and 100 ml of NADPH 2 mM, and filled with H 2 O to a final volume of 1 ml. After 10 min of incubation at 37°C, the reaction was initiated by the addition of 10 ml of t-butyl hydroperoxide, and the absorbance was measured at 340 nm. The reaction was run for 90 s, and the loss of NADPH was monitored by the change in A 340 nm /min. Catalase activity was measured according to the method developed by Aebi. 20) Erythrocytic hemolysate 100 ml or liver tissue preparation was dissolved in 50 mM phosphate buffer 50 ml (pH 7), and 2 ml of the mixture was added to a cuvette. The reaction was initiated by the addition of 1 ml of H 2 O 2 30 nM at 20°C. The H 2 O 2 decomposition rate was measured at 240 nm for 30 s using a spectrophotometer.
Plasma Total Radical Trapping Antioxidant Potential (TRAP) The plasma total radical trapping antioxidant potential (TRAP) was measured using a modification of the photometric method developed by Rice-Evans and Miller. 21) The method for measuring antioxidant activity is predicated on the antioxidant-induced inhibition of the absorbance of the radical cation of 2,2Ј-azinobis (3-ethylbenzothiazoline 6-sulfonate) (ABTS ϩ ). The ABTS ϩ radical cation is formed by the interaction of ABTS ϩ (150 mM) with the ferrylmyoglobin radical species, which is, in turn, generated by the activation of metmyoglobin (2.5 mM) by H 2 O 2 (75 mM). Ten microliters of sample/buffer/Trolox-standard was added to tubes containing 400 ml of PBS buffer, 20 ml of metmyoglobin, and 400 ml of ABTS and mixed by vortexing. The reaction was initiated by the addition of 170 ml of H 2 O 2 . After 6 min of incubation, the absorbance was measured at 734 nm using a spectrophotometer. Values are expressed as Trolox equivalent antioxidant capacity (TEAC) and defined as the millimolar concentration of the Trolox antioxidant capacity of a calibration curve.
Baseline Conjugated Dienes in LDL Baseline LDL conjugated diene levels were determined according to the methods outlined by Ahotupa et al., with slight modifications. 22 ) Plasma 100 ml was added to heparin citrate buffer 700 ml (trisodium citrate 0.064 M, heparin 50000 IU/l, pH 5.05), and this suspension was allowed to stand for 10 min at room temperature. The insoluble lipoproteins were then sedimented by centrifugation at 1000ϫg for 10 min. The pellet was resuspended in 100 ml of Na-phosphate buffer 0.1 M containing 0.9% NaCl (pH 7.4). Lipids were extracted from the 100 ml of LDL suspension with chloroform-methanol (2 : 1), dried under nitrogen, redissolved in cyclohexane, and analyzed spectrophotometrically at 234 nm. Oxidation during sample preparation was prevented by the addition of EDTA.
Statistical Analysis Data were analyzed using the SPSS package for Windows (Version 10). Values are expressed as the meansϮstandard error (S.E.). Statistical differences between the control and B. polyfermenticus-supplemented groups were considered significant at pϽ0.05 using Student's t-test. Evaluation of the associations between parameters was carried out using Pearson's correlation.
RESULTS
Food Intake, Weight Gain, and Organ Weight Body weight gain, food intake, and the food efficiency ratio (FER) did not appear to be influenced by B. polyfermenticus supplementation ( Table 1 ). The organ weights were not found to differ between the groups.
Plasma, Hepatic, and Fecal Lipid Profiles Plasma, hepatic, and fecal lipid profiles are summarized in Table 2 . B. polyfermenticus supplementation resulted in significant reductions (24%) in the levels of plasma LDL cholesterol (pϭ0.02) and nonsignificant reductions in total plasma cholesterol (14%, pϭ0.08) and the atherogenic index (30%, pϭ0.08). The ratio of HDL cholesterol to total cholesterol was significantly higher in the B. polyfermenticus group than in the control group. Triglyceride and HDL cholesterol levels were not affected by B. polyfermenticus supplementation. Hepatic total cholesterol and triglyceride levels were significantly lower in the B. polyfermenticus group than in the control group, by 55% and 21%, respectively. These significant reductions in plasma LDL cholesterol, hepatic total cholesterol, and triglyceride levels were correlated with higher fecal excretion levels of total cholesterol and triglycerides. Fecal total cholesterol and triglyceride levels were increased significantly after the administration of B. polyfermenticus SCD and elevated over control levels by 63%, and 45%, respectively. The B. polyfermenticus group exhibited a nonsignificant decrease in hepatic total lipid levels and a nonsignificant increase in fecal total lipids. Plasma TRAP, LDL Oxidation, and Erythrocytic Antioxidant Enzymes As shown in Table 3 , the TRAP value, an indicator of total antioxidant defense, was significantly affected by B. polyfermenticus SCD supplementation. B. polyfermenticus SCD led to a 14% increase in TRAP above control levels (pϽ0.001). Plasma conjugated dienes, a marker of lipid peroxidation, were reduced significantly (by 16%) in the B. polyfermenticus group as compared with the control group. The erythrocytic GSH-Px activity in the B. polyfermenticus group was significantly lower (by 18%) than that in the control group. Catalase activity in the erythrocytes exhibited a tendency to decrease after the administration of B. polyfermenticus. However, this was not a statistically significant tendency.
Correlation of Plasma TRAP, and Hepatic and Fecal Total Cholesterol Plasma TRAP levels exhibited a highly significant negative correlation with hepatic total cholesterol levels, (Fig. 1, rϭϪ0.726, pϽ0 .001) and a marginally significant negative correlation with plasma total cholesterol levels (rϭϪ0.437, pϭ0.07). However, there was a significant positive correlation between fecal total cholesterol and plasma TRAP levels (rϭ0.483, pϭ0.008).
Plasma AST, ALT, Glucose, and Protein Values No significant differences between the groups were detected with regard to plasma AST and ALT activities, and glucose, total protein, albumin, and uric acid levels (Table 4) . 
DISCUSSION
Acid and bile tolerance is considered to be an important characteristic for a probiotic, as a good probiotic survives such digestive stresses to grow and function in the small intestine.
23) The B. polyfermenticus SCD strain used in this study was previously found to have a high level of bile tolerance and acid resistance and to have a high degree of adhesive capacity to the Caco-2 cell line used as a model for human intestinal cells. 13) Moreover, administration of B. polyfermenticus SCD has been demonstrated to colonize the human intestine, reducing the number of fecal coliforms in healthy adults. 24) The results of the present study demonstrated that 6 weeks of supplementation with the probiotic B. polyfermenticus SCD (3.1ϫ10 6 cfu/d) was effective in improving cholesterol and antioxidant metabolism in rats fed a high-fat, high-cholesterol diet. B. polyfermenticus SCD resulted in significant reductions in plasma LDL cholesterol, hepatic total cholesterol, and triglyceride levels, while increasing the fecal excretion of total cholesterol and triglycerides, compared with control levels. In addition, it might also result in a reduction in the risk of atherosclerosis, because the ratio of HDL cholesterol to total cholesterol was significantly higher than in the control group.
A great deal of research has been carried out, both in animal experiments with rats and human clinical trials, on the hypocholesterolemic activity of lactic acid bacteria (LAB) and yogurt fermented with LAB, including Lactobacillus spp. and Bifidobacterium spp. 25, 26) Usman and Hosono 25) reported that Lactobacillus gasseri SBT0270 exerted its hypocholesterolemic effects by suppressing the reabsorption of bile acids into the enterohepatic circulation system and by enhancing the excretion of acidic steroids in the feces of hypercholesterolemic rats. In a placebo-controlled study, fermented milk with Lactobacillus acidophilus L1 resulted in a 2.9% reduction in serum cholesterol concentrations in hypercholesterolemic individuals. 26) Several in vitro and in vivo studies have proposed a number of mechanisms for the observed cholesterol-lowering actions of probiotic bacteria. These include the inhibition of cholesterol absorption by the binding of cholesterol to the bacterial cell wall, 27) assimilation (uptake) of cholesterol by lactic acid bacteria, 28, 29) promotion of bile acid excretion from the deconjugation of bile acid by the bacteria, 30, 31) and inhibition of hepatic cholesterol synthesis and/or the redistribution of cholesterol from plasma to the liver by the cholesterol-metabolizing enzyme systems in the liver, such as HMG-CoA reductase.
32) The cholesterollowering action of B. polyfermenticus SCD in the present study might be attributable to the binding of dietary cholesterol by B. polyfermenticus SCD before cholesterol can be absorbed into the body, thus resulting in the increased excretion of unabsorbed cholesterol in the feces. This possibility was raised in our in vitro experiment, 16) which indicated that B. polyfermenticus SCD reduced cholesterol by 60% in the culture medium during 24 h at 37°C, and that the removal of cholesterol was independent of bile acids. We also determined that cholesterol was in the cell extracts of the bacteria after cultivation, suggesting that the cholesterol-lowering action of B. polyfermenticus SCD might be due largely to the binding or assimilation of cholesterol. The exact mechanism underlying the effects of B. polyfermenticus SCD on cholesterol metabolism needs to be further elucidated.
Oxidative stress, defined as a disruption of the balance between oxidative and antioxidative processes, plays an important role in the pathogenesis of atherosclerosis. 33) A cholesterol-rich diet results in increased lipid peroxidation by the induction of free radical production, followed by hypercholesterolemia, a major risk factor for atherosclerosis. 34) The relationship between oxidative stress and cholesterol levels was confirmed in the present study, showing that plasma TRAP, an indicator of total antioxidant defense, exhibited a negative correlation with both plasma and hepatic total cholesterol levels, and a positive correlation with the fecal excretion levels of total cholesterol. Such a relationship between plasma antioxidant defense and cholesterol levels mediated by B. polyfermenticus SCD could be explained in two ways. First, the oxidative stress due to hypercholesterolemia could be reduced by decreased cholesterol levels in plasma after B. 
